A Phase 1 Dose Escalation Trial of Third-generation Anti-CD19 CAR T-cells Incorporating a Toll-like Receptor 2 (TLR2) Intracellular Domain for Relapsed or Refractory B-cell Non-Hodgkin Lymphomas
主講人：Dr Robert Weinkove
時(shí)間：2023年8月8日（星期二）15:30
地點(diǎn)：E228會(huì)議室
主持人：李鵬研究員
主講人簡(jiǎn)介：
Dr Robert Weinkove is a Haematologist at Wellington Blood & Cancer Centre and Clinical Director at the Malaghan Institute of Medical Research in New Zealand. Dr Weinkove studied medicine at the University of Cambridge and Kings College London, trained in Haematology at Guy’s and St Thomas’ Hospitals in London and at the Medizinische Hochschule Hannover in Germany, and completed an Immunology PhD with the University of Otago.
Dr Weinkove provides clinical oversight of the Malaghan Institute’s GMP cell therapy facility providing clinical-grade lentiviral vectors and closed-system automated CAR T-cell manufacture. He is Principal Investigator for ‘ENABLE’ (clinicaltrials.gov NCT04049513), a phase 1 clinical trial of WZTL-002, comprising third-generation autologous anti-CD19 CAR T-cells with a TLR2 domain, for relapsed and refractory B-cell lymphomas.
Dr Weinkove is an active member of the Australasian Leukaemia & Lymphoma Group, and contributes to cooperative group and commercial clinical trials in the field of B-cell malignancies and therapy-related immunosuppression.
